BREAKING NEWS: Fractyl Health is pleased to announce we will be accelerating our REMAIN 1 #clinicaltrial, studying our novel device’s efficacy in maintaining #weightloss following the discontinuation of GLP-1 therapy. We expect to report data starting in Q4 2024. We also announced an amendment to our REVITALIZE 1 study, expanding eligibility to patients with #T2D who are inadequately controlled on any glucose lowering agent – including GLP-1 agonists – increasing our potential treatment population in the United States by nearly six-fold. For the full #announcement, including a quote from our co-founder, read our full release: https://lnkd.in/gNS6D7DC
Fractyl Health’s Post
More Relevant Posts
-
Incredible panel today at JPM24 on GLP1 with: Sarah Emond, CEO of Institute for Clinical and Economic Review; Dan Mendelson, CEO of Morgan Health; and Asst Prof Diana Thiara, MD of University of California, San Francisco... Key discussion points: 1) Great data on efficacy of GLP1s means that payors globally cannot ignore this category of drugs. Clearly, this is becoming seminal category of drugs that will have long term health effects on relevant patient populations. Speculation around the size of the addressable market potentially reaching US$100B. 2) Biggest issue will be around affordability of GLP1s for the patient populations that need them. Unless prices come down significantly, health systems will not be able to afford the cost of making GLP1s available to the patients that need them. 3) Warnings of weight rebound and deterimental health effects for patients who are taken off GLP1 after the start of treatment. 4) Plenty of room for innovation to continue to change the market. Next-generation GLP1s, cell therapy, regenerative medicine, and business models(subscription, direct-to-patient sales). Many shifts expected in the next 12 months. Great session with outstanding panelists. I learned alot, and the summary does not do justice to the excellent discussion. #JPM24 #GLP1
To view or add a comment, sign in
-
In this K-Cast series, experts discuss adverse effects of anti-fibrotic agents and examine pharmacotherapies for IPF that are currently in phase 3 clinical trials. Watch this program to learn more about the unmet needs with IPF treatment and the future of IPF management. https://bit.ly/3VYeOSZ #ManagedCare
To view or add a comment, sign in
-
Impact of Dose Modifications on CLL Treatment: The discussion explores the frequency and impact of dose modifications due to adverse events, strategies for maintaining outcomes, monitoring protocols, and how these modifications affect long-term CLL therapy effectiveness and treatment decisions. #finance #pharmacy #lifesciences
To view or add a comment, sign in
-
Chief Commercial Officer (CCO) at NanoImaging Services. Making cryo-EM accessible to companies of all stages and sizes in the drug discovery pipeline.
Understanding the structure of the #hERG channel is vital to drug safety, and can reduce the potential for adverse cardiac ❤️ effects. Analyzing #hERG-#ligand complexes with #cryoEM 🔬 #structuredetermination can help develop safer, more effective medication. 🤔 Learn more about gaining the #3Dstructure of hERG in complex with your ligand: https://lnkd.in/gcirFEEa
To view or add a comment, sign in
-
Learn more about the clinical values of the EndoClot® Submucosal Injection System (SIS). #OlympusPost
EndoClot® Submucosal Injection System (SIS) In-Service
To view or add a comment, sign in
-
New findings about for GLP-1 agonists were published this week by researchers from Epic, an electronic health record company. Researchers found that people with diabetes who started taking most versions of GLP-1 agonists were between 11% and 65% less likely to be newly diagnosed with depression than people with diabetes who didn’t take one of the drugs. Similar reductions were observed for patients without diabetes taking the GLP-1s as well! Read the full article here: https://lnkd.in/eNBmd--E 🖥 AyaFusion.com #downersgrove #downersgroveweightloss #semaglutidewesternsuburbs #semaglutideweightloss #semaglutidechicago #lombard #lombardweightloss #tirzepatide #tirzepatideweightloss #tirzepatidechicago
To view or add a comment, sign in
-
The road to unlocking the full potential of GLP-1 agonists in treating chronic conditions is paved with obstacles. In our latest whitepaper, OPEN Health experts provide their take on the major challenges key stakeholders face and how to get past them. https://hubs.la/Q02mZll60 #WorldObesityDay #HEOR #MedComms #PatientEngagement #GLP1
OPEN Health | Unlocking the Full Potential of GLP-1 Agonists
openhealthgroup.com
To view or add a comment, sign in
-
Super interesting piece on #glp1 agonists. These are some of the most revolutionary medical innovations that came to market over the last years. It is not only about the outstending #clinical impact, it is mostly about the #social, #economic, and #ethical questions that come with these products. In this piece we try and discuss some of these questions and understand the implications for #access and #use across societies. #pharmaceuticals #marketaccess #publichealth #healthsystems
The road to unlocking the full potential of GLP-1 agonists in treating chronic conditions is paved with obstacles. In our latest whitepaper, OPEN Health experts provide their take on the major challenges key stakeholders face and how to get past them. https://hubs.la/Q02mZjTF0 #WorldObesityDay #HEOR #MedComms #PatientEngagement #GLP1
OPEN Health | Unlocking the Full Potential of GLP-1 Agonists
openhealthgroup.com
To view or add a comment, sign in
-
The road to unlocking the full potential of GLP-1 agonists in treating chronic conditions is paved with obstacles. In our latest whitepaper, OPEN Health experts provide their take on the major challenges key stakeholders face and how to get past them. #WorldObesityDay #HEOR #MedComms #patient
The road to unlocking the full potential of GLP-1 agonists in treating chronic conditions is paved with obstacles. In our latest whitepaper, OPEN Health experts provide their take on the major challenges key stakeholders face and how to get past them. https://hubs.la/Q02mZjTF0 #WorldObesityDay #HEOR #MedComms #PatientEngagement #GLP1
OPEN Health | Unlocking the Full Potential of GLP-1 Agonists
openhealthgroup.com
To view or add a comment, sign in
-
The road to unlocking the full potential of GLP-1 agonists in treating chronic conditions is paved with obstacles. In our latest whitepaper, OPEN Health experts provide their take on the major challenges key stakeholders face and how to get past them. https://hubs.la/Q02mZjWr0 #WorldObesityDay #HEOR #MedComms #PatientEngagement #GLP1
OPEN Health | Unlocking the Full Potential of GLP-1 Agonists
openhealthgroup.com
To view or add a comment, sign in
7,480 followers
General Counsel, Axogen, Inc.
3moWhat a break through if the trial is positive!!